New Haven, Conn. — Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians are presenting research studies at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) June 3-7 in Chicago, IL. This year’s scientific program will feature more than 2,800 abstracts in over 120 subcategories.
At this year’s meeting, the latest cancer research findings from Yale Cancer Center and Smilow Cancer Hospital will show new treatments and diagnostic advances in head and neck, gynecological, lung, prostate, and gastric cancers, melanoma, and many other areas of oncology. Some of the research highlights include:
A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors: Final Analysis of Efficacy and Association with MGMT (ECOG-ACRIN E2211)
Presenter: Pamela L. Kunz, MD, Director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and YaleCancer Center; Associate Professor of Medicine (Medical Oncology)
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522
Presenter: Lajos Pusztai, MD, DPhil, Professor of Medicine (Medical Oncology), Yale Cancer Center
Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study
Presenter: Tara Sanft, MD, Associate Professor of Medicine (Medical Oncology), Yale Cancer Center, Chief Patient Experience Officer and Director of Survivorship, Smilow Cancer Hospital
Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A
Senior Author: Roy S. Herbst, MD, PhD, Deputy Director for Clinical Affairs and Chief Medical Officer, Yale Cancer Center and Smilow Cancer Hospital
Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy
Presenter: Harriet Kluger, MD, Professor of Medicine (Medical Oncology), Clinical Program Leader, Melanoma, YaleCancer Center and Smilow Cancer Hospital
Targetable genomic mutations in young women with advanced breast cancer
Senior Author: Maryam Lustberg, MD, MPH, Associate Professor of Medicine (Medical Oncology) and Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center
A full list of Yale Cancer Center participation at ASCO and schedule of events can be found online.
# # #